Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Genetic basis for skin youthfulness.

Flood KS, Houston NA, Savage KT, Kimball AB.

Clin Dermatol. 2019 Jul - Aug;37(4):312-319. doi: 10.1016/j.clindermatol.2019.04.007. Epub 2019 Apr 26.

PMID:
31345318
2.

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM.

J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.

3.

Thick Melanoma Is Associated with Low Melanoma Knowledge and Low Perceived Health Competence, but Not Delays in Care.

Zhang S, Liu R, Siripong N, Kirkwood J, Holtzman MP, Davar D, Najjar Y, Marshall K, Cullison SJ, Houston NA, Switzer G, Ferris LK.

J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30872-2. doi: 10.1016/j.jaad.2019.05.068. [Epub ahead of print] No abstract available.

PMID:
31150702
4.

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.

Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.

Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.

5.

Feasibility and reliability of clinical coding surveillance for the routine monitoring of adverse drug events in New Zealand hospitals.

Ng J, Andrew P, Muir P, Greene M, Mohan S, Knight J, Hider P, Davis P, Seddon M, Scahill S, Harrison J, Zhou L, Selak V, Lawes C, Galgali G, Broad J, Crawley M, Pevreal W, Houston N, Brott T, Ryan D, Peach J, Brant A, Bramley D.

N Z Med J. 2018 Oct 26;131(1484):46-60.

PMID:
30359356
6.

Natural Explanation for 21 cm Absorption Signals via Axion-Induced Cooling.

Houston N, Li C, Li T, Yang Q, Zhang X.

Phys Rev Lett. 2018 Sep 14;121(11):111301. doi: 10.1103/PhysRevLett.121.111301.

PMID:
30265083
7.

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM.

J Transl Med. 2018 Jul 16;16(1):196. doi: 10.1186/s12967-018-1569-5.

8.

Age-induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age.

Kimball AB, Alora-Palli MB, Tamura M, Mullins LA, Soh C, Binder RL, Houston NA, Conley ED, Tung JY, Annunziata NE, Bascom CC, Isfort RJ, Jarrold BB, Kainkaryam R, Rocchetta HL, Swift DD, Tiesman JP, Toyama K, Xu J, Yan X, Osborne R.

J Am Acad Dermatol. 2018 Jan;78(1):29-39.e7. doi: 10.1016/j.jaad.2017.09.012. Epub 2017 Nov 14.

PMID:
29146147
9.

A matched comparison of human papillomavirus-induced squamous cancer of unknown primary with early oropharynx cancer.

Ross RB, Koyfman SA, Reddy CA, Houston N, Geiger JL, Woody NM, Joshi NP, Greskovich JF Jr, Burkey BB, Scharpf J, Lamarre ED, Prendes B, Lorenz RR, Adelstein DJ, Ward MC.

Laryngoscope. 2018 Jun;128(6):1379-1385. doi: 10.1002/lary.26965. Epub 2017 Oct 31.

PMID:
29086413
10.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

11.

Evaluation of a complex intervention to improve primary care prescribing: a phase IV segmented regression interrupted time series analysis.

MacBride-Stewart S, Marwick C, Houston N, Watt I, Patton A, Guthrie B.

Br J Gen Pract. 2017 May;67(658):e352-e360. doi: 10.3399/bjgp17X690437. Epub 2017 Mar 27.

12.

Biophysical properties of the clinical-stage antibody landscape.

Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Baruah H, Gray LT, Krauland EM, Xu Y, Vásquez M, Wittrup KD.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949. doi: 10.1073/pnas.1616408114. Epub 2017 Jan 17.

13.

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.

14.
15.

Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.

Ward MC, Ross RB, Koyfman SA, Lorenz R, Lamarre ED, Scharpf J, Burkey BB, Joshi NP, Woody NM, Prendes B, Houston N, Reddy CA, Greskovich JF, Adelstein DJ.

JAMA Otolaryngol Head Neck Surg. 2016 Dec 1;142(12):1164-1170. doi: 10.1001/jamaoto.2016.1876.

PMID:
27438230
16.

Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11.

Ward MC, Adelstein DJ, Bhateja P, Nwizu TI, Scharpf J, Houston N, Lamarre ED, Lorenz R, Burkey BB, Greskovich JF, Koyfman SA.

Oral Oncol. 2016 Jun;57:21-6. doi: 10.1016/j.oraloncology.2016.03.014. Epub 2016 Apr 1.

PMID:
27208840
17.

Preliminary feasibility and modelling of a liquid matrix Dictyostelium discoideum virulence assay for Pseudomonas aeruginosa.

Champion AC, Houston NK, Bradbury RS, Reid DW.

Br J Biomed Sci. 2016;73(2):51-5. doi: 10.1080/09674845.2016.1157249. Epub 2016 Apr 28.

PMID:
27181169
18.

Patient Preferences During Skin Cancer Screening Examination.

Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris LK.

JAMA Dermatol. 2016 Sep 1;152(9):1052-4. doi: 10.1001/jamadermatol.2016.1005. No abstract available.

PMID:
27166873
19.

Qualitative evaluation of the Safety and Improvement in Primary Care (SIPC) pilot collaborative in Scotland: perceptions and experiences of participating care teams.

Bowie P, Halley L, Blamey A, Gillies J, Houston N.

BMJ Open. 2016 Jan 29;6(1):e009526. doi: 10.1136/bmjopen-2015-009526.

20.

Personal Burden of Isotretinoin Therapy and Willingness to Pay for Electronic Follow-up Visits.

Mori WS, Houston N, Moreau JF, Prevost N, Gehris RP, Ferris LK, Patton TJ.

JAMA Dermatol. 2016 Mar;152(3):338-40. doi: 10.1001/jamadermatol.2015.4763. No abstract available.

PMID:
26720269
21.

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM.

Cancer. 2016 Feb 15;122(4):588-597. doi: 10.1002/cncr.29783. Epub 2015 Nov 13.

22.

The Scottish patient safety programme in primary care: context, interventions and early outcomes.

Houston N, Bowie P.

Scott Med J. 2015 Nov;60(4):192-5. doi: 10.1177/0036933015606577. Epub 2015 Oct 7. No abstract available.

PMID:
26449921
23.

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer.

Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC.

Front Oncol. 2015 Jun 1;5:123. doi: 10.3389/fonc.2015.00123. eCollection 2015.

24.

Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation.

Wanner M, Houston N, Javorsky E, Yuan M, Alora-Palli M, Kimball AB.

J Drugs Dermatol. 2015 Jan;14(1):13-8.

PMID:
25607903
25.

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.

Mol Clin Oncol. 2013 May;1(3):565-569. Epub 2013 Mar 20.

26.

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.

Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.

27.

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.

Cancer. 2013 Apr 1;119(7):1357-64. doi: 10.1002/cncr.27916. Epub 2012 Dec 20.

28.

Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst.

Houston N, Stewart N, Smith DS, Bell SC, Champion AC, Reid DW.

J Cyst Fibros. 2013 Jul;12(4):352-62. doi: 10.1016/j.jcf.2012.11.004. Epub 2012 Dec 23.

29.

The absence of heat shock protein HSP101 affects the proteome of mature and germinating maize embryos.

Lázaro-Mixteco PE, Nieto-Sotelo J, Swatek KN, Houston NL, Mendoza-Hernández G, Thelen JJ, Dinkova TD.

J Proteome Res. 2012 Jun 1;11(6):3246-58. doi: 10.1021/pr3000046. Epub 2012 May 11.

PMID:
22545728
30.

Sources and Delivery of Nutrients to the Northwestern Gulf of Mexico from Streams in the South-Central United States.

Rebich RA, Houston NA, Mize SV, Pearson DK, Ging PB, Evan Hornig C.

J Am Water Resour Assoc. 2011 Oct;47(5):1061-1086.

31.

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R.

Invest New Drugs. 2013 Feb;31(1):77-84. doi: 10.1007/s10637-012-9801-2. Epub 2012 Feb 28.

32.

Genomically biased accumulation of seed storage proteins in allopolyploid cotton.

Hu G, Houston NL, Pathak D, Schmidt L, Thelen JJ, Wendel JF.

Genetics. 2011 Nov;189(3):1103-15. doi: 10.1534/genetics.111.132407. Epub 2011 Sep 6.

33.

Comparative proteomics of seed maturation in oilseeds reveals differences in intermediary metabolism.

Hajduch M, Matusova R, Houston NL, Thelen JJ.

Proteomics. 2011 May;11(9):1619-29. doi: 10.1002/pmic.201000644. Epub 2011 Mar 17. Review.

PMID:
21413150
34.

Quantitation of soybean allergens using tandem mass spectrometry.

Houston NL, Lee DG, Stevenson SE, Ladics GS, Bannon GA, McClain S, Privalle L, Stagg N, Herouet-Guicheney C, MacIntosh SC, Thelen JJ.

J Proteome Res. 2011 Feb 4;10(2):763-73. doi: 10.1021/pr100913w. Epub 2010 Dec 8.

PMID:
21141899
35.

Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

Han JJ, Yu M, Houston N, Steinberg SM, Kohn EC.

Gynecol Oncol. 2011 Jan;120(1):5-10. doi: 10.1016/j.ygyno.2010.09.006. Epub 2010 Oct 15. Erratum in: Gynecol Oncol. 2011 May 1;121(2):427.

36.

Evolution of seed allergen quantification--from antibodies to mass spectrometry.

Stevenson SE, Houston NL, Thelen JJ.

Regul Toxicol Pharmacol. 2010 Dec;58(3 Suppl):S36-41. doi: 10.1016/j.yrtph.2010.07.001. Epub 2010 Jul 11. Review.

PMID:
20627116
37.

A quantitative mass spectrometry-based approach for identifying protein kinase clients and quantifying kinase activity.

Huang Y, Houston NL, Tovar-Mendez A, Stevenson SE, Miernyk JA, Randall DD, Thelen JJ.

Anal Biochem. 2010 Jul 1;402(1):69-76. doi: 10.1016/j.ab.2010.03.028. Epub 2010 Mar 25.

PMID:
20346904
38.

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.

Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC.

Br J Cancer. 2010 Feb 2;102(3):495-9. doi: 10.1038/sj.bjc.6605514. Epub 2010 Jan 5.

39.
40.

X-ray structure of ILL2, an auxin-conjugate amidohydrolase from Arabidopsis thaliana.

Bitto E, Bingman CA, Bittova L, Houston NL, Boston RS, Fox BG, Phillips GN Jr.

Proteins. 2009 Jan;74(1):61-71. doi: 10.1002/prot.22124.

41.

Black tea polyphenols mimic insulin/insulin-like growth factor-1 signalling to the longevity factor FOXO1a.

Cameron AR, Anton S, Melville L, Houston NP, Dayal S, McDougall GJ, Stewart D, Rena G.

Aging Cell. 2008 Jan;7(1):69-77. Epub 2007 Dec 19.

42.

Letter to the Editor.

Houston N, Thomas M, Napier A, Taylor F.

Educ Prim Care. 2006;17(2):181-182. doi: 10.1080/14739879.2006.11864058. No abstract available.

PMID:
28240064
43.

Phylogenetic analyses identify 10 classes of the protein disulfide isomerase family in plants, including single-domain protein disulfide isomerase-related proteins.

Houston NL, Fan C, Xiang JQ, Schulze JM, Jung R, Boston RS.

Plant Physiol. 2005 Feb;137(2):762-78. Epub 2005 Jan 28.

44.

Quality improvement within Independent Practitioner Associations: lessons from New Zealand.

Houston N, Coster G, Wolff L.

N Z Med J. 2001 Jul 13;114(1135):304-6.

PMID:
11556442
45.
46.

Doctor/patient relationship: caring stressed at MSU medical colleges.

Houston NM, Grauer PT.

Mich Hosp. 1983 Jan;19(1):9-11, 13. No abstract available.

PMID:
10278145
47.

Comparison of cardiovascular response to combined static-dynamic effort, postprandial dynamic effort and dynamic effort alone in patients with chronic ischemic heart disease.

Hung J, McKillip J, Savin W, Magder S, Kraus R, Houston N, Goris M, Haskell W, DeBusk R.

Circulation. 1982 Jun;65(7):1411-9.

PMID:
6280892
48.
49.

MSU's entering medical class over 50 percent female.

Houston NM.

Mich Med. 1981 Nov;80(32):614-6. No abstract available.

PMID:
7311882
50.

Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment.

Sami M, Harrison DC, Kraemer H, Houston N, Shimasaki C, DeBusk RF.

Am J Cardiol. 1981 Jul;48(1):147-56. No abstract available.

PMID:
6787910

Supplemental Content

Loading ...
Support Center